Christopher G. Bunick, MD, PhD

Christopher G. Bunick, MD, PhD, is editor in chief of Dermatology Times and an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut.

Articles by Christopher G. Bunick, MD, PhD

Understanding the Psychosocial Burden of Plaque Psoriasis

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Jashin Wu, MD,Helen Torok, MD

December 23rd 2021

Considerations for the psychological and social impact that plaque psoriasis may have on a patient.

Challenges in Diagnosing Plaque Psoriasis

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Jashin Wu, MD,Helen Torok, MD

December 23rd 2021

Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis

Identifying Clinical Manifestations of Plaque Psoriasis

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Jashin Wu, MD,Helen Torok, MD

December 16th 2021

Shared insight on identifying clinical manifestations of plaque psoriasis and making a timely diagnosis.

Pathophysiology of Plaque Psoriasis and Targeted Therapies

ByChristopher G. Bunick, MD, PhD,Mark G. Lebwohl, MD,Helen Torok, MD,Jashin Wu, MD

December 16th 2021

A panel of experts review the nature of plaque psoriasis and the mechanism of action of several classes of targeted therapy.

Christopher G. Bunick, MD, PhD

Articles by Christopher G. Bunick, MD, PhD

Understanding the Psychosocial Burden of Plaque Psoriasis

Challenges in Diagnosing Plaque Psoriasis

Identifying Clinical Manifestations of Plaque Psoriasis

Pathophysiology of Plaque Psoriasis and Targeted Therapies

Trending on Dermatology Times

Clascoterone 5% Topical Solution Shows Long-Term Promise for Male Pattern Hair Loss

Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol

Dersimelagon NDA Accepted by FDA with Priority Review for EPP, XLP

Patidegib Gel Completes Phase 3 Follow-Up in Gorlin Syndrome

Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study